Collaborative double robust targeted maximum likelihood estimation

International Journal of Biostatistics

Volumn 6, Issue 1, 2010, Pages

  Van Der Laan, Mark J ^a   Gruber, Susan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Asymptotic linearity; Causal effect; Censored data; Coarsening at random; Collaborative double robust; Cross validation; Double robust; Efficient influence curve; Estimating function; Estimator selection; G computation; Influence curve; Locally efficient

Indexed keywords

ARTICLE; CAUSAL MODELING; COLLABORATIVE TARGETED MAXIMUM LIKELIHOOD ESTIMATION; CONFIDENCE INTERVAL; LEARNING; LINEAR SYSTEM; MAXIMUM LIKELIHOOD METHOD; METHODOLOGY; PARAMETER; PROBABILITY; RESEARCH; STANDARD; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS; BIOMETRY; COMPARATIVE STUDY; COMPUTER SIMULATION; HUMAN; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL;

BIOMETRY; COMPUTER SIMULATION; CONFIDENCE INTERVALS; DATA INTERPRETATION, STATISTICAL; HUMANS; LIKELIHOOD FUNCTIONS; PROBABILITY; REGRESSION ANALYSIS;

EID: 77953150321     PISSN: 15574679     EISSN: None     Source Type: Journal    
DOI: 10.2202/1557-4679.1181     Document Type: Article

References (67)

1. P.K. Andersen, O. Borgan, R.D. Gill, and N. Keiding. Statistical Models Based on Counting Processes. Springer-Verlag New York, 1993.
2. O. Bembom, M.L. Petersen, S.-Y. Rhee, W. J. Fessel, S.E. Sinisi, R.W. Shafer, and M.J. van der Laan. Biomarker discovery using targeted maximum likelihood estimation: Application to the treatment of antiretroviral resistant hiv infection. Statistics in Medicine, page http://www3.interscience.wiley.com/ journal/121422393/abstract, 2008.
3. O. Bembom, M.J. van der Laan, T. Haight, and I.B. Tager. Lifetime and current leisure time physical activity and all-cause mortality in an elderly cohort. Epidemiology, 2009.
4. Oliver Bembom and Mark van der Laan. Statistical methods for analyzing sequentially randomized trials, commentary on JNCI article Adaptive therapy for androgen independent prostate cancer: A randomized selection trial including four regimens, by Peter F. Thall, C. Logothetis, C. Pagliaro, S. Wen, M.A. Brown, D. Williams, R. Millikan (2007). Journal of the National Cancer Institute, 99(21):1577-1582, 2007.
5. P.J. Bickel, C.A.J. Klaassen, Y. Ritov, and J. Wellner. Efficient and Adaptive Estimation for Semiparametric Models. Springer-Verlag, 1997.
6. J. Bryan, Z. Yu, and M.J. van der Laan. Analysis of longitudinal marginal structural models. Biostatistics, 5(3):361-380, 2003.
7. S. Dudoit and M.J. van der Laan. Asymptotics of cross-validated risk estimation in estimator selection and performance assessment. Statistical Method-ology, 2(2):131-154, 2005.
8. R. Gill and J.M. Robins. Causal inference in complex longitudinal studies: continuous case. Ann. Stat., 29(6), 2001.
9. R.D. Gill, M.J. van der Laan, and J.M. Robins. Coarsening at random: characterizations, conjectures and counter-examples. In D.Y. Lin and T.R. Fleming, editors, Proceedings of the First Seattle Symposium in Biostatistics, pages 255-94, New York, 1997. Springer Verlag.
10. D.F. Heitjan and D.B. Rubin. Ignorability and coarse data. Annals of statis-tics, 19(4):2244-2253, December 1991.
11. M. A. Hernan, B. Brumback, and J. M. Robins. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology, 11(5):561-570, 2000.
12. M. Jacobsen and N. Keiding. Coarsening at random in general sample spaces and random censoring in continuous time. Annals of Statistics, 23:774-86, 1995.
13. J. Kang and J. Schafer. Demystifying double robustness: A comparison of alternative strategies for estimating a population mean from incomplete data (with discussion). Statistical Science, 22:523-39, 2007a.
14. J. Kang and J. Schafer. Rejoinder: Demystifying double robustness: A comparison of alternative strategies for estimating a population mean from incomplete data. Statistical Science, 22:574-80, 2007b.
15. S. Keleş, M. van der Laan, and S. Dudoit. Asymptotically optimal model selection method for regression on censored outcomes. Technical Report, Division of Biostatistics, UC Berkeley, 2002.
16. K.L. Moore and M.J. van der Laan. Covariate adjustment in randomized trials with binary outcomes. Technical report 215, Division of Biostatistics, University of California, Berkeley, April 2007.
17. K.L. Moore and M.J. van der Laan. Application of time-to-event methods in the assessment of safety in clinical trials. In Karl E. Peace, editor, in Design, Summarization, Analysis & Interpretation of Clinical Trials with Time-to-Event Endpoints. Chapman and Hall, 2009.
18. S.A. Murphy. Optimal dynamic treatment regimes. Journal of the Royal Statistical Society: Series B, 65(2), 2003.
19. S.A. Murphy, M.J. van der Laan, and J.M. Robins. Marginal mean models for dynamic treatment regimens. Journal of the American Statistical Associa-tion, 96:1410-1424, 2001.
20. R. Neugebauer and M.J. van der Laan. Why prefer double robust estimates. Journal of Statistical Planning and Inference, 129(1-2):405-426, 2005.
21. Maya L. Petersen, Steven G. Deeks, Je rey N. Martin, and Mark J. van der Laan. History-adjusted marginal structural models: Time-varying effect modi cation and dynamic treatment regimens. Technical report 199, Division of Biostatistics, University of California, Berkeley, December 2005.
22. E.C. Polley and M.J. van der Laan. Predicting optimal treatment assignment based on prognostic factors in cancer patients. In Karl E. Peace, editor, in Design, Summarization, Analysis & Interpretation of Clinical Trials with Time-to-Event Endpoints. Chapman and Hall, 2009.
23. G. Ridgeway and D. McCa rey. Comment: Demystifying double robustness: A comparison of alternative strategies for estimating a population mean from incomplete data (with discussion). Statistical Science, 22:540-43, 2007.
24. J. Robins, L. Orallana, and A. Rotnitzky. Estimaton and extrapolation of optimal treatment and testing strategies. Statistics in Medicine, 27(23): 4678-4721, 2008.
25. J. M. Robins and A. Rotnitzky. Comment on the Bickel and Kwon article, "Inference for semiparametric models: Some questions and an answer". Sta-tistica Sinica, 11(4):920-936, 2001a.
26. J. M. Robins, M. A. Hernan, and B. Brumback. Marginal structural models and causal inference in epidemiology. Epidemiology, 11(5):550-560, 2000a.
27. J. M. Robins, A. Rotnitzky, and M.J. van der Laan. Comment on "On Pro le Likelihood" by S.A. Murphy and A.W. van der Vaart. Journal of the Amer-ican Statistical Association { Theory and Methods, 450:431-435, 2000b.
28. J. M. Robins, M. Sued, Q. Lei-Gomez, and A. Rotnitzky. Comment: Performance of double-robust estimators when "inverse probability" weights are highly variable. Statistical Science, 22:544-559, 2007.
29. J.M. Robins. Robust estimation in sequentially ignorable missing data and causal inference models. In Proceedings of the American Statistical Associ-ation, 2000a.
30. J.M. Robins. Discussion of "optimal dynamic treatment regimes" by susan a. murphy. Journal of the Royal Statistical Society: Series B, 65(2):355-366, 2003.
31. J.M. Robins. Optimal structural nested models for optimal sequential decisions. In Heagerty P.J Lin, D.Y, editor, Proceedings of the 2nd Seattle symposium in biostatistics, volume 179, pages 189-326, 2005a.
32. J.M. Robins. Optimal structural nested models for optimal sequential decisions. Technical report, Department of Biostatistics, Havard University, 2005b.
33. J.M. Robins. A new approach to causal inference in mortality studies with sustained exposure periods - application to control of the healthy worker survivor effect. Mathematical Modelling, 7:1393-1512, 1986.
34. J.M. Robins. The analysis of randomized and non-randomized aids treatment trials using a new approach in causal inference in longitudinal studies. In L. Sechrest, H. Freeman, and A. Mulley, editors, Health Service Methodology: A Focus on AIDS, pages 113-159. U.S. Public Health Service, National Center for Health SErvices Research, Washington D.C., 1989.
35. J.M. Robins. Information recovery and bias adjustment in proportional hazards regression analysis of randomized trials using surrogate markers. In Proceeding of the Biopharmaceutical section, pages 24-33. American Statistical Association, 1993.
36. J.M. Robins. Causal inference from complex longitudinal data. In Editor M. Berkane, editor, Latent Variable Modeling and Applications to Causality, pages 69-117. Springer Verlag, New York, 1997a.
37. J.M. Robins. Structural nested failure time models. In P. Armitage, T. Colton, P.K. Andersen, and N. Keiding, editors, The Encyclopedia of Biostatistics. John Wiley and Sons, Chichester, UK, 1997b.
38. J.M. Robins. Marginal structural models versus structural nested models as tools for causal inference. In Statistical models in epidemiology, the environ-ment, and clinical trials (Minneapolis, MN, 1997), pages 95-133. Springer, New York, 2000b.
39. J.M Robins and A. Rotnitzky. Comment on Inference for semiparametric models: some questions and an answer, by Bickel, P.J. and Kwon, J. Statistica Sinica, 11:920-935, 2001b.
40. J.M. Robins and A. Rotnitzky. Recovery of information and adjustment for dependent censoring using surrogate markers. In AIDS Epidemiology, Methodological issues. Bikhäuser, 1992.
41. S. Rose and M.J. van der Laan. Simple optimal weighting of cases and controls in case-control studies. The International Journal of Biostatistics, page http://www.bepress.com/ijb/vol4/iss1/19/., 2008.
42. S. Rose and M.J. van der Laan. Why match? investigating matched casecontrol study designs with causal effect estimation. The International Jour-nal of Biostatistics, page http://www.bepress.com/ijb/vol5/iss1/1/., 2009.
43. P.R. Rosenbaum and D.B. Rubin. The central role of the propensity score in observational studies for causal effects. Biometrika, 70:41-55, 1983.
44. M. Rosenblum, S.G. Deeks, M.J. van der Laan, and D.R. Bangsberg. The risk of virologic failure decreases with duration of hiv suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE, 4(9): e7196.doi:10.1371/journal.pone.0007196, 2009.
45. D.B. Rubin. Matched Sampling for Causal Effects. Cambridge University Press, Cambridge, MA, 2006.
46. D.B. Rubin and M.J. van der Laan. Empirical efficiency maximization: Improved locally Efficient covariate adjustment in randomized experiments and survival analysis. The International Journal of Biostatistics, Vol.4, Iss. 1, Article 5, 2008.
47. J.S. Sekhon. Multivariate and propensity score matching software with automated balance optimization: The matching package for R. Journal of Statistical Sotware, Forthcoming, 2008.
48. S. Sinisi and M.J. van der Laan. The deletion/substitution/addition algorithm in loss function based estimation: Applications in genomics. Journal of Statistical Methods in Molecular Biology, 3(1), 2004.
49. Z. Tan. Comment: Understanding or, ps and dr. Statistical Science, 22: 560-568, 2007.
50. A. Tsiatis and M. Davidian. Comment: Demystifying double robustness: A comparison of alternative strategies for estimating a population mean from incomplete data (with discussion). Statistical Science, 22:569-73, 2007
51. C. Tuglus and M.J. van der Laan. Targeted methods for biomarker discovery, the search for a standard. UC Berkeley Working Paper Series, page http://www.bepress.com/ucbbiostat/paper233/., 2008.
52. M.J. van der Laan. Causal effect models for intention to treat and realistic individualized treatment rules. Technical report 203, Division of Biostatistics, University of California, Berkeley, 2006.
53. M.J. van der Laan. Estimation based on case-control designs with known prevalance probability. The International Journal of Biostatistics, page http://www.bepress.com/ijb/vol4/iss1/17/, 2008a.
54. M.J. van der Laan. The construction and analysis of adaptive group sequential designs. Technical report 232, Division of Biostatistics, University of California, Berkeley, March 2008b.
55. M.J. van der Laan and S. Dudoit. Unified cross-validation methodology for selection among estimators and a general cross-validated adaptive epsilon-net estimator: Finite sample oracle inequalities and examples. Technical report, Division of Biostatistics, University of California, Berkeley, November 2003.
56. M.J. van der Laan and M.L. Petersen. Causal effect models for realistic individualized treatment and intention to treat rules. International Journal of Biostatistics, 3(1), 2007.
57. M.J. van der Laan and J.M. Robins. Unified methods for censored longitudinal data and causality. Springer, New York, 2003.
58. M.J. van der Laan and D. Rubin. Targeted maximum likelihood learning. The International Journal of Biostatistics, 2(1), 2006.
59. M.J. van der Laan, S. Dudoit, and S. Keles. Asymptotic optimality of likelihood-based cross-validation. Statistical Applications in Genetics and Molecular Biology, 3, 2004.
60. M.J. van der Laan, M.L. Petersen, and M.M. Joffe. History-adjusted marginal structural models and statically-optimal dynamic treatment regimens. The International Journal of Biostatistics, 1(1):10-20, 2005.
61. M.J. van der Laan, S. Dudoit, and A.W. van der Vaart. The cross-validated adaptive epsilon-net estimator. Statistics and Decisions, 24(3):373-395, 2006.
62. M.J. van der Laan, E. Polley, and A. Hubbard. Super learner. Statistical Applications in Genetics and Molecular Biology, 6(25), 2007. ISSN 1.
63. M.J. van der Laan, S. Rose, and S. Gruber. Readings on targeted maximum likelihood estimation. Technical report, working paper series http://www.bepress.com/ucbbiostat/paper254/, September, 2009.
64. A. van der Vaart and J. Wellner. Weak Convergence and Empirical Processes. Springer-Verlag, New York, 1996.
65. A.W. van der Vaart, S. Dudoit, and M.J. van der Laan. Oracle inequalities for multi-fold cross-validation. Statistics and Decisions, 24(3):351-371, 2006.
66. Z. Yu and M.J. van der Laan. Construction of counterfactuals and the Gcomputation formula. Technical report, Division of Biostatistics, University of California, Berkeley, 2002.
67. Z. Yu and M.J. van der Laan. Double robust estimation in longitudinal marginal structural models. Technical report, Division of Biostatistics, University of California, Berkeley, 2003.